



Attorney Docket No.: 6034.200-US

RECEIVED
FEB 29 2002
TECH CENTER 1600/2900
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Serial No.: 09/891,691

Group Art Unit: To be assigned

Filed: June 26, 2001

Examiner: To be assigned

Confirmation No.: 1796

For: Use of Potassium Channel Agonists for Reducing Fat Food Consumption

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on January 3, 2002.

Carol McFarlane-Fishberg
(name of person mailing paper)

Carol McFarlane-Fishberg
(signature of person mailing paper)



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6034.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 09/891,691

Group Art Unit: To be assigned

Filed: June 26, 2001

Examiner: To be assigned

Confirmation No.: 1796

For: Use of Potassium Channel Agonists for Reducing Fat Food Consumption

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. WO 00/37474;
2. WO 99/03861;
3. WO 97/26265;
4. WO 97/26264;
5. WO 99/32494;

6. WO 97/49692;
7. WO 94/25033;
8. EP 0 618 209 A1;
9. Pirotte et al., J. Med. Chem., Vol. 43, pgs. 1456-1466 (2000);
10. Alemzadeh et al., Endocrinology, Vol. 133, pgs. 705-712 (1993);
11. Alemzadeh et al., Journal of Clinical Endocrinology and Metabolism, Vol. 83, pgs. 1911-1915 (1998);
12. Standridge et al., The FASEB Journal, Vol. 14, pgs. 455-460 (2000);
13. Ghelardini et al., European Journal of Pharmacology, Vol. 329, pgs. 1-8 (1997);
14. Del Prete et al., Pharmacology Biochemistry and Behavior, Vol. 53, pgs. 839-842 (1996);
15. Roane et al., Pharmacology Biochemistry and Behavior, Vol. 46, pgs. 205-207 (1993);
16. Levin et al., Am. J. Physiol., Vol. 276, (Regulatory Integrative Comp. Physiol, Vol. 45), pgs. R1223-R1231 (1999);
17. Larue-Achagiotis et al., Pharmacology Biochemistry & Behavior, Vol. 9, pgs. 717-720 (1978);
18. Rossi et al., Journal of Autonomic Nervous System, Vol. 56, pgs. 45-49 (1995);
19. Alemzadeh et al., Endocrinology, Vol. 140, pgs 3197-3202 (1999); and
20. Abstract of C. Larue-Achagiotis, Neuroscience Letters, Vol. 10, Suppl. 1, pg. S56 (1978).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,



Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE